Oncternal Therapeutics Analyst Ratings
Oncternal Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/18/2023 | 471.43% | HC Wainwright & Co. | → $2 | Upgrades | Neutral → Buy |
| 09/07/2023 | 271.43% | Cantor Fitzgerald | → $1.3 | Reiterates | Neutral → Neutral |
| 06/06/2023 | — | HC Wainwright & Co. | Reiterates | → Neutral | |
| 04/04/2023 | — | Maxim Group | Downgrades | Buy → Hold | |
| 04/04/2023 | — | Brookline Capital | Downgrades | Buy → Hold | |
| 04/04/2023 | 271.43% | Cantor Fitzgerald | $4 → $1.3 | Maintains | Overweight |
| 04/04/2023 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 04/04/2023 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 03/22/2023 | 2471.43% | Oppenheimer | $14 → $9 | Maintains | Outperform |
| 03/14/2023 | 1900% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 12/22/2022 | 1042.86% | Cantor Fitzgerald | → $4 | Initiates Coverage On | → Overweight |
| 08/10/2022 | 1900% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 05/10/2022 | 900% | Maxim Group | → $3.5 | Initiates Coverage On | → Buy |
| 02/24/2022 | 1328.57% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 04/07/2021 | 3900% | Oppenheimer | → $14 | Initiates Coverage On | → Outperform |
| 03/30/2021 | 4471.43% | Brookline Capital | → $16 | Initiates Coverage On | → Buy |
| 03/12/2021 | 2471.43% | HC Wainwright & Co. | $8 → $9 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/18/2023 | 471.43% | HC Wainwright公司 | →$2 | 升級 | 中性→購買 |
| 09/07/2023 | 271.43% | 康託·菲茨傑拉德 | →$1.3 | 重申 | 中性→中性 |
| 06/06/2023 | - | HC Wainwright公司 | 重申 | →中性 | |
| 04/04/2023 | - | Maxim集團 | 評級下調 | 購買→Hold | |
| 04/04/2023 | - | 布魯克林資本 | 評級下調 | 購買→Hold | |
| 04/04/2023 | 271.43% | 康託·菲茨傑拉德 | $4→$1.3 | 維護 | 超重 |
| 04/04/2023 | - | HC Wainwright公司 | 評級下調 | 購買→中性 | |
| 04/04/2023 | - | 奧本海默 | 評級下調 | 超越→表現 | |
| 03/22/2023 | 2471.43% | 奧本海默 | $14→$9 | 維護 | 跑贏大盤 |
| 03/14/2023 | 1900% | HC Wainwright公司 | →$7 | 重申 | →購買 |
| 2022年12月22日 | 1042.86% | 康託·菲茨傑拉德 | →$4 | 開始承保 | →超重 |
| 2022年08月10日 | 1900% | HC Wainwright公司 | $8→$7 | 維護 | 買 |
| 2022年05月10日 | 900% | Maxim集團 | →$3.5 | 開始承保 | →購買 |
| 02/24/2022 | 1328.57% | BTIG | →$5 | 開始承保 | →購買 |
| 04/07/2021 | 3900% | 奧本海默 | →$14 | 開始承保 | →跑贏大盤 |
| 03/30/2021 | 4471.43% | 布魯克林資本 | →$16 | 開始承保 | →購買 |
| 03/12/2021 | 2471.43% | HC Wainwright公司 | $8→$9 | 維護 | 買 |
What is the target price for Oncternal Therapeutics (ONCT)?
腫瘤治療公司(ONCT)的目標價格是多少？
The latest price target for Oncternal Therapeutics (NASDAQ: ONCT) was reported by HC Wainwright & Co. on September 18, 2023. The analyst firm set a price target for $2.00 expecting ONCT to rise to within 12 months (a possible 471.43% upside). 11 analyst firms have reported ratings in the last year.
腫瘤治療公司(納斯達克代碼：ONCT)的最新目標價是由HC Wainwright&Co.於2023年9月18日報道的。這家分析公司將目標價定為2美元，預計ONCT將在12個月內上漲至(可能上漲471.43%)。過去一年，有11家分析公司公佈了評級。
What is the most recent analyst rating for Oncternal Therapeutics (ONCT)?
腫瘤治療公司(ONCT)的最新分析師評級是多少？
The latest analyst rating for Oncternal Therapeutics (NASDAQ: ONCT) was provided by HC Wainwright & Co., and Oncternal Therapeutics upgraded their buy rating.
昂科特治療公司(納斯達克市場代碼：ONCT)的最新分析師評級由HC Wainwright&Co.提供，Oncent治療公司上調了其買入評級。
When is the next analyst rating going to be posted or updated for Oncternal Therapeutics (ONCT)?
腫瘤治療公司(ONCT)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oncternal Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oncternal Therapeutics was filed on September 18, 2023 so you should expect the next rating to be made available sometime around September 18, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Oncent Treeutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Oncent Treeutics的上一次評級是在2023年9月18日提交的，所以你應該預計下一次評級將在2024年9月18日左右提供。
Is the Analyst Rating Oncternal Therapeutics (ONCT) correct?
分析師對Onctal Treeutics(ONCT)的評級正確嗎？
While ratings are subjective and will change, the latest Oncternal Therapeutics (ONCT) rating was a upgraded with a price target of $0.00 to $2.00. The current price Oncternal Therapeutics (ONCT) is trading at is $0.35, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Onctal Treeutics(ONCT)評級被上調，目標價從0.00美元到2.00美元。Onctal Treateutics(ONCT)目前的交易價格為0.35美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。